Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 19;220(4):635-642.
doi: 10.1093/infdis/jiz144.

Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV

Affiliations

Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV

Mary Morrow et al. J Infect Dis. .

Abstract

Background: Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF). However, its value as a predictor of future viremia remained unknown.

Methods: Blood for plasma viral load (VL) and TFV-DP in DBS were collected (up to 3 visits within 48 weeks) in PLWH on TDF. TFV-DP cut points were selected using logistic prediction models maximizing the area under the receiver operation characteristic curve, and estimated adjusted odds ratio (aOR) of future viremia (≥20 copies/mL) were compared to the highest TFV-DP category.

Results: Among all 451 participants in the analysis, aOR of future viremia for participants with TFV-DP <800 and 800 to <1650 fmol/punch were 4.7 (95% CI, 2.6-8.7; P < .0001) and 2.1 (95% CI, 1.3-3.3; P = .002) versus ≥1650 fmol/punch, respectively. These remained significant for participants who were virologically suppressed at the time of the study visit (4.2; 95% CI, 1.5-12.0; P = .007 and 2.2; 95% CI, 1.2-4.0; P = .01).

Conclusions: TFV-DP in DBS predicts future viremia in PLWH on TDF, even in those who are virologically suppressed. This highlights the utility of this biomarker to inform about adherence beyond VL. Clinical Trials Registration. NCT02012621.

Keywords: adherence; antiretroviral therapy; dried blood spots; pharmacokinetics; predictive value; tenofovir diphosphate.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trajectory of TFV-DP in DBS in participants in whom drug concentrations were available for all 3 study visits (N = 213) according to drug concentration category. Colors represent TFV-DP categories with green indicating higher concentrations (≥1650 fmol/punch), yellow medium concentrations (800 to <1650 fmol/punch), and red low concentrations (BLQ to <800 fmol/punch) of TFV-DP. Each line within each category represents 1 participant. Individuals with the same progression of TFV-DP over time are grouped together forming thicker color bands. At visit 2, n = 115, n = 74, and n = 24 participants were included in the high, medium, and low concentrations, respectively. Abbreviations: BLQ, below limit of quantification; DBS, dried blood spots; TFV-DP, tenofovir diphosphate.

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.ttps://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 10 June 2014.
    1. Cohen MS, Chen YQ, McCauley M, et al. ; HPTN 052 Study Team Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375:830–9. - PMC - PubMed
    1. Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Current HIV/AIDS Reports 2018; 15:1–11. - PMC - PubMed
    1. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10:227–45. - PMC - PubMed
    1. Bisson GP, Gross R, Bellamy S, et al. . Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5:e109. - PMC - PubMed

Publication types

Associated data